(Q38861026)

7 September 2017

1 reference

title

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations (English)

1 reference

7 September 2017

1 reference

1 reference

1 reference

1 reference

Hampig Raphael Kourie

1

object named as

Hampig Raphael Kourie

1 reference

7 September 2017

Marie Chaix

2

1 reference

7 September 2017

Andrea Gombos

3

1 reference

7 September 2017

Phillippe Aftimos

4

1 reference

7 September 2017

Ahmad Awada

5

1 reference

7 September 2017

language of work or name

English

0 references

publication date

10 June 2016

1 reference

Expert Opinion on Drug Metabolism & Toxicology

7 September 2017

1 reference

7 September 2017

12

1 reference

7 September 2017

8

1 reference

7 September 2017

947-957

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Primary trastuzumab resistance: new tricks for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

ErbB receptors: new insights on mechanisms and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Role of HER2/HER3 co-receptor in breast carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Activating HER2 mutations in HER2 gene amplification negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

The development of HKI-272 and related compounds for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Antitumor activity of HER-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Characterization of HKI-272 covalent binding to human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1198317

10.1080/17425255.2016.1198317

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference